Inmune Bio Stock Price on December 9, 2024
INMB Stock | USD 4.95 0.30 5.71% |
Below is the normalized historical share price chart for INmune Bio extending back to February 04, 2019. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of INmune Bio stands at 4.95, as last reported on the 12th of December 2024, with the highest price reaching 4.95 and the lowest price hitting 4.95 during the day.
If you're considering investing in INmune Stock, it is important to understand the factors that can impact its price. At this point, INmune Bio is slightly risky. INmune Bio holds Efficiency (Sharpe) Ratio of 0.0046, which attests that the entity had a 0.0046% return per unit of risk over the last 3 months. We have found twenty-one technical indicators for INmune Bio, which you can use to evaluate the volatility of the firm. Please check out INmune Bio's Standard Deviation of 4.42, risk adjusted performance of (0.01), and Market Risk Adjusted Performance of (0.06) to validate if the risk estimate we provide is consistent with the expected return of 0.019%.
At present, INmune Bio's Common Stock is projected to increase significantly based on the last few years of reporting. The current year's Capital Stock is expected to grow to about 857.9 K, whereas Total Stockholder Equity is forecasted to decline to about 33.6 M. . At present, INmune Bio's Price Book Value Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 5.57, whereas Price To Sales Ratio is forecasted to decline to 1,241. INmune Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 4th of February 2019 | 200 Day MA 8.0815 | 50 Day MA 5.3518 | Beta 1.852 |
INmune |
Sharpe Ratio = 0.0046
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | INMB |
Estimated Market Risk
4.09 actual daily | 36 64% of assets are more volatile |
Expected Return
0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average INmune Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of INmune Bio by adding INmune Bio to a well-diversified portfolio.
Price Book 3.0098 | Enterprise Value Ebitda (5.31) | Price Sales 2.8 K | Shares Float 14.3 M | Wall Street Target Price 19.8333 |
Related Headline
Anebulo Pharmaceuticals Headline on 9th of December 2024
Acquisition by Cunningham, Richard Anthony of 254433 shares ... by MacroaxisInsider
Filed transaction by Anebulo Pharmaceuticals Director, Officer: Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
INmune Bio Valuation on December 9, 2024
It is possible to determine the worth of INmune Bio on a given historical date. On December 9, 2024 INmune was worth 4.93 at the beginning of the trading date compared to the closed value of 5.32. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of INmune Bio stock. Still, in general, we apply an absolute valuation method to find INmune Bio's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of INmune Bio where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against INmune Bio's related companies.
Open | High | Low | Close | Volume | |
4.90 | 4.96 | 4.81 | 4.90 | 128,486 | |
12/09/2024 | 4.93 | 5.36 | 4.93 | 5.32 | 195,215 |
5.33 | 5.68 | 5.27 | 5.44 | 253,124 |
Backtest INmune Bio | | | INmune Bio History | | | INmune Bio Valuation | Previous | Next |
INmune Bio Trading Date Momentum on December 9, 2024
On December 10 2024 INmune Bio was traded for 5.44 at the closing time. The top price for the day was 5.68 and the lowest listed price was 5.27 . The trading volume for the day was 253.1 K. The trading history from December 10, 2024 was a factor to the next trading day price jump. The trading delta at closing time against the next closing price was 2.26% . The trading delta at closing time against the current closing price is 1.32% . |
INmune Bio Fundamentals Correlations and Trends
By evaluating INmune Bio's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among INmune Bio's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. INmune financial account trend analysis is a perfect complement when working with valuation or volatility modules.About INmune Bio Stock history
INmune Bio investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for INmune is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in INmune Bio will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing INmune Bio stock prices may prove useful in developing a viable investing in INmune Bio
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 18 M | 14.8 M | |
Net Loss | -24.6 M | -23.3 M |
INmune Bio Quarterly Net Working Capital |
|
INmune Bio Stock Technical Analysis
INmune Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
INmune Bio Period Price Range
Low | December 12, 2024
| High |
0.00 | 0.00 |
INmune Bio cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
INmune Bio December 12, 2024 Market Strength
Market strength indicators help investors to evaluate how INmune Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading INmune Bio shares will generate the highest return on investment. By undertsting and applying INmune Bio stock market strength indicators, traders can identify INmune Bio entry and exit signals to maximize returns
INmune Bio Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for INmune Bio's price direction in advance. Along with the technical and fundamental analysis of INmune Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of INmune to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | (0.01) | |||
Jensen Alpha | (0.30) | |||
Total Risk Alpha | (0.82) | |||
Treynor Ratio | (0.07) |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |